This study is ongoing, but not recruiting participants. Official Title Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women – The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Detailed Description: The original base protocol was extended. Subjects in the placebo arm […]
For complete information on Gardasil, as promoted in Europe, you can obtain access to the authorisation details, product information and their assessment history via this link.
Proper Name: Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant Trade name: Gardasil Manufacturer: Merck & Co., Inc, License #0002 Product Information and Supporting Documents Approval History, Letters, Reviews, and Related Documents – Gardasil
Manufacturer, Merck & Co. To obtain product information on Gardasil or Silgard directly from the manufacturer, you can visit their website and search for product by name. Visit Merck’s database here.
VRBPAC Briefing Document Presented by Merck on 17 November 2010 Human papillomaviruses (HPV) cause a significant burden of benign and malignant anogenital disease in men and women. The HPV-related anogenital cancers all develop through a common pathogenetic process of neoplastic change that begins with the necessary event of HPV infection. After cervical cancer, the anogenital […]